View in EDS

368TiPSTART: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306).

Saved in:
Bibliographic Details
Title: 368TiPSTART: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306).
Authors: Bonnefoi, H1 (AUTHOR), Levy, C2 (AUTHOR), MacGrogan, G3 (AUTHOR), Grellety, T1 (AUTHOR), Asselain, B4 (AUTHOR), Pulido, M5 (AUTHOR), Everhard, S6 (AUTHOR), Lemonnier, J6 (AUTHOR), Gonçalves, A7 (AUTHOR)
Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy272.356